CN CULTURAL T&A(00542): The sales process for the flagship project Germany City is expected to be completed by the end of 2025.
China Culture & Tourism Agriculture (00542) announced that the group has four developmental projects, located in Germany City in Hengqin, etc.
CN CULTURAL T&A (00542) announced that the group has four development projects, namely the German City project in Hengqin, the Fuyuan Junting project in Chengdu, the Fuyuan Square project in Doumen, and the Taishan project in Taishan City.
The board of directors is pleased to inform shareholders and potential investors that following the pre-sale in the fourth quarter of 2019, the sales process for one of the group's flagship projects, German City, is expected to be largely completed by the end of 2025, pending the completion of construction for the project.
The group has recently entered into a sale agreement with an independent third party for the bulk sale of 12 buildings in German City, with a total contract price of approximately RMB 550 million. This transaction is expected to be completed by the end of 2025.
This transaction marks a significant sales milestone for the group. The expected proceeds from the sale are expected to significantly improve the group's cash flow, strengthen the balance sheet, and have a positive impact on overall financial performance. This also demonstrates the group's ability to develop and monetize large-scale comprehensive projects.
Related Articles

Tesla, Inc. (TSLA.US) is being investigated by the NHTSA for door handle problems.

SAMPLE TECH (01708) plans to publicly list for sale part of the land use rights of industrial real estate in Nanjing City.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) plans to apply for US regulatory approval for the high-dose Wegovy.
Tesla, Inc. (TSLA.US) is being investigated by the NHTSA for door handle problems.

SAMPLE TECH (01708) plans to publicly list for sale part of the land use rights of industrial real estate in Nanjing City.

Novo Nordisk A/S Sponsored ADR Class B (NVO.US) plans to apply for US regulatory approval for the high-dose Wegovy.
